This study shows that a short course of bortezomib may be effective in one-third of patients with symptomatic CAD failing previous treatments, with acceptable toxicity and longlasting benefit in the majority of responding patients. These data provide a rationale for further investigating the potential benefits of bortezomib either by using a more prolonged treatment schedule or in combination with other agents, particularly rituximab.
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study / Rossi, G., Gramegna, D., Paoloni, F., Fattizzo, B., Binda, F., D’Adda, M., Farina, M., Lucchini, E., Mauro, F.R., Salvi, F., Marchetti, M., Fazi, P., Zaja and Wilma Barcellini, F.. - In: BLOOD. - ISSN 0006-4971. - ELETTRONICO. - 8:11(2018), pp. 547-550. [10.1182/blood-2018-03-835413]
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study
Francesca Romana MauroWriting – Review & Editing
;
2018
Abstract
This study shows that a short course of bortezomib may be effective in one-third of patients with symptomatic CAD failing previous treatments, with acceptable toxicity and longlasting benefit in the majority of responding patients. These data provide a rationale for further investigating the potential benefits of bortezomib either by using a more prolonged treatment schedule or in combination with other agents, particularly rituximab.| File | Dimensione | Formato | |
|---|---|---|---|
|
Rossi_short-course_2018.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
624.09 kB
Formato
Adobe PDF
|
624.09 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
